NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Tatva Chintan Pharma Chem Limited (NSE: TATVA)
TATVA Technical Analysis
2.5
As on 9th May 2025 TATVA SHARE Price closed @ 738.65 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 890.55 & Strong Buy for SHORT-TERM with Stoploss of 702.39 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TATVASHARE Price
Open | 700.10 | Change | Price | % |
High | 763.00 | 1 Day | 15.00 | 2.07 |
Low | 700.10 | 1 Week | 35.05 | 4.98 |
Close | 738.65 | 1 Month | 89.35 | 13.76 |
Volume | 25324 | 1 Year | -427.55 | -36.66 |
52 Week High 1843.25 | 52 Week Low 952.10 |
NSE INDIA Most Active Stocks
YESBANK | 20.02 | 9.82% |
IDEA | 6.70 | 0.15% |
GTLINFRA | 1.35 | -0.74% |
SUZLON | 52.67 | -0.90% |
UNIONBANK | 122.90 | 6.33% |
APOLLO | 130.31 | 11.76% |
WELSPUNLIV | 146.90 | 6.53% |
RPOWER | 38.65 | 1.02% |
BEL | 315.85 | 2.83% |
CANBK | 97.64 | 2.38% |
NSE INDIA Top Gainers Stocks
NSE INDIA Top Losers Stocks
MUTHOOTMF | 129.26 | -11.62% |
GRINDWELL | 1611.70 | -9.01% |
ARTNIRMAN | 41.31 | -7.34% |
SONATSOFTW | 365.70 | -6.85% |
MEDICO | 50.46 | -6.49% |
SURYODAY | 114.96 | -6.45% |
ACEINTEG | 22.50 | -6.21% |
HPIL | 113.23 | -6.11% |
HPIL | 113.23 | -6.11% |
CHOLAHLDNG | 1718.00 | -6.07% |
TATVA Daily Charts |
TATVA Intraday Charts |
Whats New @ Bazaartrend |
TATVA Free Analysis |
|
TATVA Important Levels Intraday
RESISTANCE | 859.86 |
RESISTANCE | 820.99 |
RESISTANCE | 796.96 |
RESISTANCE | 772.93 |
SUPPORT | 704.37 |
SUPPORT | 680.34 |
SUPPORT | 656.31 |
SUPPORT | 617.44 |
TATVA Target May 2025
4th UP Target | 975.49 |
3rd UP Target | 889.46 |
2nd UP Target | 836.29 |
1st UP Target | 783.11 |
1st DOWN Target | 631.39 |
2nd DOWN Target | 578.21 |
3rd DOWN Target | 525.04 |
4th DOWN Target | 439.01 |
TATVA Weekly Target
4th UP Target | 863.44 |
3rd UP Target | 812.18 |
2nd UP Target | 780.49 |
1st UP Target | 748.81 |
1st DOWN Target | 658.39 |
2nd DOWN Target | 626.71 |
3rd DOWN Target | 595.02 |
4th DOWN Target | 543.76 |
TATVA Target2025
4th UP Target | 2785.48 |
3rd UP Target | 2177.43 |
2nd UP Target | 1801.58 |
1st UP Target | 1425.73 |
1st DOWN Target | 353.27 |
2nd DOWN Target | -22.58 |
3rd DOWN Target | -398.43 |
4th DOWN Target | -1006.48 |
Tatva Chintan Pharma Chem Limited ( NSE INDIA Symbol : TATVA )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
TATVA Synopsis Technicals View
50 Day EMA |
N/A (Short Term) |
N/A | |
100 Day EMA | N/A (Mid Term) | N/A | |
200 Day EMA | N/A (Long Term) | N/A | |
MACD (12 26 9) | N/A | N/A | |
RSI (14) | N/A | N/A | |
MFI (14) | N/A | N/A | |
CCI (20) | N/A | N/A | |
WILLIAM %R (14) | N/A | N/A | |
ADX (14) | N/A | N/A | |
PSAR | N/A | N/A | |
10 Day Avg Volume | N/A |
TATVA Other Details
Segment | EQ | |
Market Capital | 0.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
TATVA Address
![]() |
TATVA Latest News
TATVA Business Profile
N/A
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service